Acadia Pharmaceuticals has announced that a small trial of its experimental sleep therapy delivered promising results. The 45 patients enlisted for the study received one of four doses of ACP-103 or a placebo. Two of the four doses demonstrated significant responses. The 5 milligram dose was associated with a 73 percent increase in deep sleep by the 13th day while the 20 milligram dose increased deep sleep by 46 percent by the 13th day.
"These data provide a proof-of-concept of the ability of ACP-103 to improve the quality of sleep by increasing slow wave sleep," said Uli Hacksell, Ph.D., CEO of ACADIA. "Acadia is currently in Phase II clinical development with ACP-103 for use in schizophrenia and treatment-induced dysfunctions in Parkinson's disease, two indications with patients who frequently suffer from sleep disturbances."
- here's the AP report for more information